Table 2.

Global comparison of breast cancer stages, population-based data

Continent/country	Stage I	Stage II	Stage III	Stage IV
Europe
Europe, 2010–2014 (OECD) (n = 2,700,348) (OECD. Health at a Glance 2020)	51	29**		10
Sweden, 2004–2009 (n = 3760) (Abdoli et al. 2017)	47	44	5	4
England, 2012 (n = 42.071) (McPhail et al.2015)	37	34	9	6
Europe, OD (n = 70,832)*	22	38	14	26
Asia
Korea, 2018 (n = 10,496) (Kang et al.2018)	43	27	7	1
Japan, 2006 (n = 20,412) (Sonoo et al. 2008)	44	45	9	3
Hong Kong, 1997–2001 (n = 7449) (Kwong et al. 2011)	26	56	13	5
China, 1999–2008 (n = 4211) (Li et al. 2011 Aug)	16	45	19	2
Philippines, 1993–2002 (n = 7152) (Laudico et al.2009)	7	52	26	16
Asia, OD (n = 18,208) *	23	44	19	14
Latin America
Brazil, 2000–2012 (n = 170,757) (Renna Junior and Silva 2018 Mar)	19	41	30	9
Mexico, 2005–2014 (n = 4411) ( Maffuz-Aziz et al.2017)	36	45**		8
Latin America, OD (n = 10,529)*	18	35	26	20
World
United States, 2007–2013 (SEER 18 registries) (Surveillance, Epidemiology, and End Results 2016)	49	34	11	6
United States, 2017 (n = 10,066) (Zimmer et al. 2018)	48	36	10	3
New Zealand, 2000–2013 (n = 12,390) (Seneviratne et al. 2016)	43	37	15	5

Percentages corrected to exclude stage 0 and unknown stage as well as unclassifiable BC. Percentages may not sum to 100 due to rounding

*Data from the OD database

**Data is represented as locally advanced Stage II and III BC